melanoma cell growth

4'-bromo-Resveratrolis a potent inhibitor of the deacetylases sirtuin 1 (SIRT1) and 3 (SIRT3)

Cytochalasin D is an actin inhibitor, the removal of actin stress fibers is crucial for the chondrogenic differentiation. It may be an inhibitor of some fertilization processes such as sperm penetration or sperm head decondensation. Cytochalasin D inhibit

Sabizabulin (ABI-231) is a potent, orally bioavailable α- and β-tubulin inhibitor that is active against melanoma and prostate cancer cell lines. Sabizabulin inhibits tumor growth and metastatic phenotypes of cervical cancer cells by targeting HPV E6 and E7 and is also being studied in prostate cancer.

ND-322 HCl (ND 322 Hydrochloride) is a selective inhibitor of MT1-MMP and MMP2 and reduces in vitro melanoma cell growth, migration and invasion.

OB 24 hydrochloride is a selective, orally active HO-1 inhibitor (IC50=1.9 μM) exhibiting antitumor and anti-metastatic properties, suitable for studying prostate cancer, melanoma, ovarian cancer, and lung cancer metastasis.

SIJ1777 is a pyrimidopyrimidinone class type II pan-BRAF inhibitor, optimized as a derivative of GNF-7. It exerts anti-tumor effects by simultaneously inhibiting the phosphorylation and activation of the MAPK pathway (MEK/ERK) and the PI3K/AKT pathway. The core advantage of SIJ1777 is its ability to maintain double-digit nanomolar GI50 values against class II/III BRAF mutants (non-V600 mutants) and NRAS-mutant melanoma cells that are insensitive to current clinical drugs (such as vemurafenib, PLX8394), effectively inducing apoptosis and blocking tumor cell migration and anchorage-independent growth.

FJ9 is an effective Wnt/β-catenin antagonist (Ki = 29 μM) that downregulates canonical Wnt signaling, inhibits HSC (hepatic stellate cell) activation, and reduces MeCP2 protein levels. FJ9 also disrupts the protein-protein interaction between Frz7 and the DVL PDZ domain, induces apoptosis in human cancer cell lines, and inhibits tumor growth in a mouse xenograft model.

3,4-Dihydroxybenzylamine hydrobromide (NSC-263475 hydrobromide) inhibits DNA polymerase activity in melanoma cells and displays growth inhibitory activity in melanoma cell lines with varying degrees of tyrosinase activity.

EOAI3402143 inhibits Usp9x and Usp24 activity, increases tumor cell apoptosis. EOAI3402143 phenocopies the FAS induction and apoptotic sensitization of Usp5 knockdown and fully blocks melanoma tumor growth.

Mensacarcin, a highly complex polyketide compound, exhibits multifaceted effects on cellular processes. Specifically, it targets mitochondria, perturbs energy metabolism within these organelles, and activates caspase-dependent apoptotic pathways. Functionally, Mensacarcin can serve as a cytotoxic constituent in antibody-drug conjugates (ADCs). Furthermore, this antibiotic compound displays broad-spectrum inhibition of cell growth across various cancer cell lines and demonstrates potent induction of apoptosis in melanoma cells.

Chemically modified tetracyclines (CMTs) can inhibit MMPs, but lack antimicrobial activity. Nonantimicrobial derivative of tetracycline called incyclinide (COL-3, CMT-3). Incyclinide (CMT-3) has been shown to experimentally suppress prostate cancer, colon adenocarcinoma and melanoma invasiveness in cell culture and to inhibit tumor growth and metastasis.

UC-112 is a novel, potent IAP inhibitor that effectively inhibits cell growth in two human melanoma and two human prostate cancer cell lines (IC50=0.7-3.4 uM).

CHI-KAT8i5 is a selective inhibitor of KAT8 with a KD of 19.72 μM. It induces apoptosis (Apoptosis) in a dose-dependent manner. CHI-KAT8i5 can inhibit tumor growth in esophageal squamous cell carcinoma, colon cancer, melanoma, gastric cancer, non-small cell adenocarcinoma, and liver cancer.

SR-2890 is a potent and highly selective casein kinase 1δ/1ε (CK1δ/ε) inhibitor with an IC50 of 4 nM for CK1δ. This compound inhibits melanoma A375 cell growth with an EC50 of 38 nM in MTT assays and possesses pharmacokinetic properties suitable for xenograft studies using human cancer cell lines.

GJ19 is a PD-L1 inhibitor with an IC50 of 32.06 nM. It binds effectively to human and mouse PD-L1 proteins, exhibiting KD values of 171 nM and 290 nM, respectively. In a co-culture model of HepG2/hPD-L1 and Jurkat T/hPD-1 cells, GJ19 promotes HepG2 cell death in a concentration-dependent manner. In the B16-F10 melanoma mouse model, GJ19 demonstrates significant tumor growth inhibition. GJ19 is applicable in tumor immunotherapy research.

IKP-104 is a microtubule/tubulin inhibitor (IC50 = 1.31 μM) that halts cells in mitosis and the M phase by inhibiting microtubule assembly and inducing cytoskeleton microtubule depolymerization. It suppresses the growth of both murine and human tumor cell lines, exhibiting antitumor effects in mouse ascites tumor and lung cancer models. IKP-104 is applicable in research on cancers such as leukemia, lung cancer, and melanoma.

Tubulin polymerization-IN-84 can inhibit the polymerization process of tubulin (Tubulin) by targeting the colchicine-binding pocket, with an IC50 value of 10.9 μM. Tubulin polymerization-IN-84 exhibits antiproliferative activity against four cell lines, namely Jurkat, B16-F10, HCT116 and MDA-MB-231, with corresponding IC50 values of 60 nM, 380 nM, 138 nM and 1.054 μM, respectively. In B16-F10 cells, Tubulin polymerization-IN-84 can induce G2/M phase cell cycle arrest and further trigger cell apoptosis. In addition, in the B16-F10 melanoma model, it can effectively inhibit the growth of tumor tissue; when combined with PD-L1 monoclonal antibody, it can also enhance the in vivo anti-tumor immune response, and can be used in the related research fields of T-cell acute lymphoblastic leukemia, melanoma, colon cancer and breast cancer.

2,5-Epidithia-3,6-dioxopiperazine (Formula 15) is a derivative of Epidithiodioxopiperazine (ETP). It enhances cell permeability and restores the activity of 2-Cys-Prx, especially peroxidase II (PrxII), within stimulated cells. This compound inhibits PDGF-induced proliferation and migration of vascular smooth muscle cells while promoting VEGF-induced endothelial cell growth and movement. Furthermore, 2,5-Epidithia-3,6-dioxopiperazine effectively suppresses the proliferation, migration, and pulmonary metastasis of melanoma cells. It holds potential for research on vascular diseases such as hypertension, angina, and myocardial infarction.

LW106 is a selective IDO1 inhibitor with an IC50 of 1.57 μM. It does not inhibit IDO2 and TDO. LW106 suppresses tumor growth by limiting substrate immune crosstalk and enriching cancer stem cells (CSC) within the tumor microenvironment. It reduces CSC subpopulations in xenograft tumors, leading to decreased tumor cell proliferation/invasiveness and inducing apoptosis. LW106 is applicable in research on lung cancer and melanoma.

Tubulin polymerization-IN-86 (Compound B6) is a potent inhibitor of tubulin polymerization. It effectively hinders microtubule assembly by binding to the colchicine site on tubulin, disrupting the microtubule cytoskeleton within cells. This compound exhibits strong antiproliferative activity against various cancer cell lines, induces cell cycle arrest and apoptosis, and inhibits cell migration, invasion, and long-term survival. Furthermore, Tubulin polymerization-IN-86 has demonstrated the ability to suppress tumor growth in mice, making it a valuable agent for melanoma research.

MEK-IN-7 (compound WX086) is a potent, orally bioavailable, selective MEK inhibitor with an MEK1 IC50 of 29.62 nM. It effectively inhibits cell proliferation in HT29 and A375 cells, with IC50 values of 0.62 nM and 0.40 nM, respectively, and suppresses tumor growth in HL-29 xenograft mouse models. MEK-IN-7 is applicable in melanoma and colon cancer research.

NHI-2 is a lactate dehydrogenase A (LDHA) inhibitor with an IC50 value of 14.7 µM, demonstrating high selectivity for LDHA over LDHB, for which the IC50 is 55.8 µM. NHI-2 functions as an efficient anti-glycolytic agent, enhancing apoptosis, inducing cell cycle arrest at the S and G2 phases, and exerting broad-spectrum antiproliferative effects in cancer cells. NHI-2 additionally affects extracellular acidification rates and ATP production and has demonstrated tumor growth suppression in murine B78 melanoma models, highlighting its role in cancer metabolism research.

NSC49652 triggers apoptotic cell death dependent on p75NTR and JNK activity in neurons and melanoma cells, and inhibits tumor growth in a melanoma mouse model.

AMG-628 is an effective and ATP-competitive RAF kinase inhibitor. AMG-628 has been shown to inhibit growth and induce cell cycle arrest and apoptosis in colon and melanoma cell lines with B-RAFV600E mutations.